Inhibition of human metapneumovirus replication by small interfering RNA

Antiviral Therapy

Volumn 13, Issue 6, 2008, Pages 821-832

  Deffrasnes, Céline ^a   Cavanagh, Marie Hélène ^a   Goyette, Nathalie ^a   Cui, Kunyuan ^b   Ge, Qing ^b,c   Seth, Shaguna ^b   Templin, Michael V ^b   Quay, Steven C ^b   Johnson, Paul H ^b,d   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

^b MDRNA Inc   (United States)

^c SomaGenics Inc   (United States)

^d PhaseRx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; MESSENGER RNA; PHOSPHOPROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN METAPNEUMOVIRUS; IC 50; IMMUNOASSAY; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA INTERFERENCE; SEQUENCE ANALYSIS; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; BASE SEQUENCE; CELL LINE; HUMANS; INHIBITORY CONCENTRATION 50; METAPNEUMOVIRUS; PARAMYXOVIRIDAE INFECTIONS; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA, VIRAL; TRANSFECTION; VIRUS REPLICATION;

EID: 53149093611     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7:719-724.
2. Deffrasnes C, Hamelin ME, Boivin G. Human metapneumovirus. Semin Respir Crit Care Med 2007; 28:213-221.
3. Broor S, Bharaj P. Avian and human metapneumovirus. Ann N Y Acad Sci 2007; 1102:66-85.
4. Boivin G, Abed Y, Pelletier G, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002; 186:1330-1334.
5. Boivin G, De Serres G, Hamelin ME, et al. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis 2007; 44:1152-1158.
6. Louie JK, Schnurr DP, Pan CY, et al. A summer outbreak of human metapneumovirus infection in a long-term-care facility. J Infect Dis 2007; 196:705-708.
7. Hamelin ME, Prince GA, Gomez AM, Kinkead R, Boivin G. Human metapneumovirus infection induces long-term pulmonary inflammation associated with airway obstruction and hyperresponsiveness in mice. J Infect Dis 2006; 193:1634-1642.
8. Garcia-Garcia ML, Calve, C, Casas I, et al. Human metapneumovirus bronchiolitis in infancy is an important risk factor for asthma at age 5. Pediatr Pulmonol 2007; 42:458-464.
9. Boivin G, Mackay I, Sloots TP, et al. Global genetic diversity of human metapneumovirus fusion gene. Emerg Infect Dis 2004; 10:1154-1157.
10. Mackay IM, Bialasiewicz S, Jacob KC, et al. Genetic diversity of human metapneumovirus over 4 consecutive years in Australia. J Infect Dis 2006; 193:1630-1633.
11. Mackay IM, Bialasiewicz S, Waliuzzaman Z, et al. Use of the P gene to genotype human metapneumovirus identifies 4 viral subtypes. J Infect Dis 2004; 190:1913-1918.
12. Manoha C, Espinosa S, Aho SL, Huet F, Pothier P. Epidemiological and clinical features of hMPV, RSV and RVs infections in young children. J Clin Virol 2007; 38:221-226.
13. van den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA. Analysis of the genomic sequence of a human metapneumovirus. Virology 2002; 295:119-132.
14. Cowton VM, McGivern DR, Fearns R. Unravelling the complexities of respiratory syncytial virus RNA synthesis. J Gen Virol 2006; 87:1805-1821.
15. Easton AJ, Domachowske JB, Rosenberg HF. Animal pneumoviruses: molecular genetics and pathogenesis. Clin Microbiol Rev 2004; 17:390-412.
16. Barik S. Control of nonsegmented negative-strand RNA virus replication by siRNA. Virus Res 2004; 102:27-35.
17. Skiadopoulos MH, Biacchesi S, Buchholz UJ, et al. Individual contributions of the human metapneumovirus F, G, and SH surface glycolyroteins to the induction of neutralizing antibodies and protective immunity. Virology 2006; 345:492-501.
18. Ulbrandt ND, Ji H, Patel NK, et al. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol 2006; 80:7799-7806.
19. Padhi A, Verghese B. Positive natural selection in the evolution of human metapneumovirus attachment glycoprotein. Virus Res 2008; 131:121-131.
20. Baulcombe D. RNA silencing in plants. Nature 2004; 431:356-363.
21. Wang MB, Metzlaff M. RNA silencing and antiviral defense in plants. Curr Opin Plant Biol 2005; 8:216-222.
22. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007; 6:443-453.
23. Anderson EM, Birmingham A, Baskerville S, et al. Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA 2008; 14:853-861.
24. Ui-Tei K, Naito Y, Zenno S, et al. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 2008; 36:2136-2151.
25. Yuan YR, Pei Y, Ma JB, et al. Crystal structure of A. aeolicus argonaute, a site-specific DNA-guided endoribonuclease, provides insights into RISC-mediated mRNA cleavage. Mol Cell 2005; 19:405-419.
26. Barik S, Bitko V. Prospects of RNA interference therapy in respiratory viral diseases: update 2006. Expert Opin Biol Ther 2006; 6:1151-1160.
27. Bitko V, Barik S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol 2001; 1:34.
28. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11:50-55.
29. Ge Q, Eisen HN, Chen J. Use of siRNAs to prevent and treat influenza virus infection. Virus Res 2004; 102:37-42.
30. Ge Q, Filip L, Bai A, et al. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A 2004; 101:8676-8681.
31. Ge Q, McManus MT, Nguyen T, et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci U S A 2003; 100:2718-2723.
32. Zhang W, Yang H, Kong X, et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 2005; 11:56-62.
33. Munir S, Kaur K, Kapur V. Avian metapneumovirus phosphoprotein targeted RNA interference silences the expression of viral proteins and inhibits virus replication. Antiviral Res 2006; 69:46-51.
34. Ferreira HL, Spilki FR, de Almeida RS, Santos MM, Arns CW. Inhibition of avian metapneumovirus (AMPV) replication by RNA interference targeting nucleoprotein gene (N) in cultured cells. Antiviral Res 2007; 74:77-81.
35. Kong X, Zhang W, Lockey RF, et al. Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet Vaccines Ther 2007; 5:4.
36. Deffrasnes C, Hamelin ME, Prince GA, Boivin G. Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob Agents Chemother 2008; 52:279-287.
37. Thermo Fisher Scientific Inc. Dharmacon RNAi Technologies, siDesign® Centre. (Accessed 26 August 2008.) Available from http://www.dharmacon.com/DesignCenter/DesignCenterPage.aspx
38. Whitehead Institute for Biomedical Research. WI siRNA selection program. (Accessed 26 August 2008.) Available from http://jura.wi.mit.edu/bioc/ siRNAext
39. DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008; 77:225-231.
40. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418:435-438.
41. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev 2004; 18:504-511.
42. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo J 2001; 20:6877-6888.
43. Wiegand MA, Bossow S, Schlecht S, Neubert WJ. De novo synthesis of N and P proteins as a key step in Sendai virus gene expression. J Virol 2007; 81:13835-13844.
44. Wyde PR, Cherry SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003; 60:51-59.
45. Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008; 26:561-569.
46. Kim DH, Behlke MA, Rose SD, et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005; 23:222-226.
47. Siolas D, Lerner C, Burchard J, et al. Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 2005; 23:227-231.
48. Amarzguioui M, Lundberg P, Cantin E, et al. Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc 2006; 1:508-517.
49. Kubo T, Zhelev Z, Ohba H, Bakalova R. Modified 27-nt dsRNAs with dramatically enhanced stability in serum and long-term RNAi activity. Oligonucleotides 2007; 17:445-464.
50. de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008; 19:125-132.
51. Novobrantseva TI, Akinc A, Borodovsky A, d Fougerolles A. Delivering silence: advancements in developing siRNA therapeutics. Curr Opin Drug Discov Devel 2008; 11:217-224.